Think this guy did previous with a negative slant. So now he is hedging his bets a bit. But he still perpetuates the fallacy that the trial was 'halted' for 2yrs:-
To further complicate the matter, in 2015, the Food and Drug Administration halted DCVax-L's clinical trial.
And he gives this baloney:-
Even with a potential survival head start compared to other clinical trials due to a screening criterion requiring patients to be progression-free before enrollment, patients' survival in the two cohorts of DCVax-L's clinical trial compares very favorably to historical rates.
What is he talking about? All these ndGBM trials require subjects to be progression free at the time of enrolment.
Anything Out Of Motley Fool NOT WORTH Paying Attention To..
Their Whole Strategy Is To High Light A Given COMPANY/////
And Then, Regardless Of What The Company Under Discussion Does Or Does Not, Pumping Companies That Are Listed Under Their Client Subscription Package....
Worse among Bad Pay Per Investment Ideas Companies...